GlassScriptPhysician profile
Mark L Hornfeld
NPI 1467428573
$45,203.80
in general payments reported to CMS, 2019-2025
22 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $601 · 2021: $42K · 2022: $432 · 2023: $330 · 2024: $912 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $41,255.92 | 2021 | |
| Allergan, INC. | $553.25 | 2019-2022 | |
| Abbvie INC. | $476.65 | 2022-2025 | |
| Alcon Vision LLC | $420.79 | 2022-2025 | Simbrinza, Eysuvis, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $396.71 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $325.57 | 2020-2025 | Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $311.32 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $310.65 | 2022-2025 | Vyzulta, Prolensa, Miebo |
| Tarsus Pharmaceuticals, INC. | $305.07 | 2024-2025 | Xdemvy |
| Amgen INC. | $222.86 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $144.30 | 2020-2022 | |
| Harrow Eye, LLC | $112.58 | 2024-2025 | Iheezo, Vevye, Ilevro |
| Kala Pharmaceuticals, INC. | $96.06 | 2019 | |
| Horizon Therapeutics Plc | $40.95 | 2023 | Tepezza |
| Shire North American Group INC | $40.17 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $34.59 | 2021 | |
| Sight Sciences, INC. | $33.68 | 2021-2023 | Tearcare System |
| Glaukos Corporation | $29.80 | 2024 | Idose |
| Dompe US, INC. | $27.33 | 2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $22.51 | 2020 | |
| Thea Pharma INC. | $22.20 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $20.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$63,088.83 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hornfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.